X0306 4 2023-02-24 1 0001868734 CinCor Pharma, Inc. CINC 0001853903 Allison David D. C/O CINCOR PHARMA, INC. 230 THIRD AVENUE, 6TH FLOOR WALTHAM MA 02451 1 0 0 0 Stock Option (Right to Buy) 13.60 2023-02-24 4 D 0 29411 D 2031-12-09 Common Stock 29411 0 D Stock Option (Right to Buy) 19.55 2023-02-24 4 D 0 1038 D 2032-04-07 Common Stock 1038 0 D Stock Option (Right to Buy) 20.20 2023-02-24 4 D 0 881 D 2032-07-07 Common Stock 881 0 D Stock Option (Right to Buy) 33.49 2023-02-24 4 D 0 524 D 2032-10-06 Common Stock 524 0 D Stock Option (Right to Buy) 11.78 2023-02-24 4 D 0 1499 D 2033-01-05 Common Stock 1499 0 D Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right ("CVR") per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share (the "Milestone Payment"), in cash, upon the achievement of a specified milestone by December 31, 2033. At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than the Cash Amount was accelerated and became fully vested and exercisable and automatically converted into the right to receive, upon the occurrence of the Milestone Payment Date (as defined in the CVR Agreement), an amount in cash equal to the product of (a) the total number of Shares subject to such option immediately prior to the effective time of the merger multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the Milestone Payment exceeds (2) the exercise price payable per Share under such option. /s/ Amanda Gonzalez Burton, Attorney-in-Fact 2023-02-24